Abstract Body

HIV incidence is a direct metric of HIV intervention and prevention trial efficacy. Incidence assay performance is evaluated by mean duration of recent infection (MDRI) and false-recent rate (FRR). A low FRR is required for accurate incidence determination and a higher MDRI allows incidence estimation from a smaller sample size. There is an immediate need for an assay meeting performance standards (MDRI > 1 year and FRR < 1%) to estimate incidence using a single measure.

We conducted a meta-analysis of HIV envelope genes sequenced from 438 incident specimens and 305 chronic specimens representing a wide range of geographic locations, subtypes, risk behaviors, ART experiences, viral loads and CD4 T cell counts. The genomic assay’s FRR was measured from chronic specimens collected at least 2 years after documented HIV infection using the genome similarity index (GSI) as a biomarker of recency. The incident specimens included 186 serial HIV sequence samples likely collected within 6 months of infection (Fiebig stage IV). In order to estimate the MDRI, we statistically modeled the average GSI dynamics with a logistic regression assuming individual variabilities in a Beta distribution. We then tested our genomic assay by sequencing 407 HIV envelope gene segments from 15 Women’s Interagency HIV Study (WIHS) seroconverters who were followed from HIV negative status. To assess how closely the WIHS cohort GSI dynamics resemble the Beta distribution estimate, each WIHS specimen’s standardized residual was evaluated and the Anderson-Darling test was conducted.

All except one chronic specimen had GSIs below 0.67, yielding a FRR of 0.33 [0-1.0] % with a 2-year cutoff. The GSI probability density function estimated from 438 incident specimens peaked close to a GSI of 1 in early infection and a GSI of 0 around 2 years post infection. Around 1 year post infection the GSI probability density function peaked at both ends of the GSI spectrum. The resulting MDRI was estimated to be 420 [357, 469] days. Both standardized residuals and the Anderson-Darling tests suggest that our WIHS cohort sequence dataset was statistically consistent with the model GSI dynamics.

This is the first incidence assay conforming to FRR and MDRI performance standards. Signatures of HIV gene diversification offer a foundation for a precise genomic assay with a desirable temporal range of incidence detection. Our finding suggests great promise for realizing accurate cross-sectional incidence surveys.